Orforglipron trial exit interviews report energy and appetite gains beyond HbA1c

The wire

1. 01Qualitative exit interviews with 60 US patients from the ACHIEVE-3 trial of oral orforglipron versus oral semaglutide found 88.3% cited glycemic control and 83.3% weight reduction as positive changes.
2. 02Spontaneously reported benefits included increased energy (46.7%), reduced appetite and cravings (38.3%) and improved exercise (30.0%); all 59 respondents said they were satisfied with the trial drug.
3. 03The interviews were designed to capture positive experiences only, were conducted at ten sites, and the sample is small relative to the parent trial.

From the source

Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes

The patient · 2026 Oct 16 · Boye K, Cutts K, Zhao Y et al.